From drought to demand: Biotech IPOs roar back with Kailera and Alamar

Strong demand for GLP-1 drugs and next-gen diagnostic testing is pulling investors back into life sciences, even as AI soaks ...

Alamar Biosciences debuts on Nasdaq as protein-detection firm eyes cancer, heart disease

Alamar Biosciences plans to seek Food and Drug Administration clearance next year for a diagnostic version of its ...
Fierce Biotech

Alamar Biosciences files for IPO amid opening life sciences funding window

Californian protein sequencing company Alamar Biosciences is seeking an IPO worth up to $159 million amid a growing boom in ...
East Oregonian

Alamar Biosciences Launches Certified Service Provider Program to Expand Access to NULISA technology for Academic and Biopharmaceutical Researchers

FREMONT, Calif., Feb. 20, 2025 /PRNewswire/ — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the launch of its ...

Cathie Wood's Ark Invest buys proteomics company Alamar, Netflix; trims crypto names

Cathie Wood’s ARK Invest made a series of targeted portfolio adjustments across its active ETFs during the last week, though ...